Why the study?
Does hydrochlorothiazide and lisinopril combination improve HOMA-IR compared to hydrochlorothiazide monotherapy in Nigerian patients with essential hypertension?
Does hydrochlorothiazide and lisinopril combination improve HOMA-IR compared to hydrochlorothiazide monotherapy in Nigerian patients with essential hypertension?
Hydrochlorothiazide monotherapy in Nigerian patients with essential hypertension was not associated with significant worsening of insulin resistance compared to combination therapy with lisinopril over 12 weeks.
Low-dose HCT may preserve beta-cell function in Nigerians; leaves open ethnic differences versus other populations.
OBJECTIVE: To assess the effects of hydrochlorothiazide (HCT) given alone and in combination with an angiotensin-converting enzyme inhibitor (ACEI) on beta-cell function in a negroid population to further explore possible ethnic differences in the effect of antihypertensive drugs on homeostasis model assessment - insulin resistance (HOMA-IR). MATERIALS AND METHODS: A total of 80 newly diagnosed Nigerian essential hypertensive patients were assigned to receive either HCT 25 mg daily or both HCT and lisinopril (Lis; 25/10 mg daily) in an open-label study for 12 weeks. The treatment groups were well matched in clinical and demographic baseline features. Changes in HOMA-IR from baseline to end of study (week 12), fasting plasma glucose (FPG), serum potassium, serum insulin, and blood pressure over the same period were also evaluated. RESULTS: = 0.913 (HCT + Lis); an insignificant increase was observed in FPG and serum insulin in both groups, whereas serum potassium decreased in similar fashion. Blood pressure reduction was similar in both groups. Analysis of HOMA-IR change according to gender in response to HCT mono- or combination therapy with Lis showed no significant difference. CONCLUSIONS: HCT monotherapy in hypertensive indigenous Nigerians, was not associated with worse metabolic effects when compared with combination therapy using Lis, an ACEI after 12 weeks. Low-dose thiazide diuretic as first-line antihypertensive medication may be safe in the short-term, further larger and long-term studies are needed to corroborate this finding.
No takes yet. Share an insight, caveat, or question.
Olamoyegun et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: